A Guide for School Health Professionals
Made possible through an unrestricted educational grant from Shire Pharmaceuticals
This ACHA online educational activity concluded in June 2007; however, the complete monograph remains available as an educational resource.
TARGET AUDIENCE
This educational activity is designed for college and secondary school health professionals.
STATEMENT OF NEED
Alcohol and substance misuse and abuse affect a large percentage of US high school and college students. Alcohol abuse and illicit drug use often receive more attention, but a growing US health concern is centered on the misuse of prescription stimulant medications often prescribed for the treatment of attention-deficit/hyperactivity disorder (ADHD). With these issues at the forefront, high school and college health providers must be aware of the prevalence and seriousness of prescription stimulant misuse among US students, strategies to identify and counsel those students engaging in stimulant misuse, and appropriate methods for assessment, diagnosis, and treatment of ADHD.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Identify the essential components of an ADHD assessment
- Describe the elements involved in the comprehensive management of ADHD
- Discuss the prevalence of stimulant misuse/abuse among high school and college students
- Explain the potential long- and short-term consequences of stimulant misuse/abuse
- Identify the presenting signs and symptoms of stimulant misuse/abuse
- List strategies for improving management of stimulant use on high school and college campuses
AUTHORS
Keith J. Anderson, PhD
Staff Psychologist
Rensselaer Polytechnic Institute
Troy, New York
Donald E. Greydanus, MD
Professor, Pediatrics and Human Development
Michigan State University College of Human Medicine
Kalamazoo Center for Medical Studies
Sindecuse Health Center
Western Michigan University
Kalamazoo, Michigan
J. Russell Ramsay, PhD
Associate Professor of Psychology in Psychiatry
Department of Psychiatry
Associate Director, Adult ADHD Treatment and Research Program
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
Anthony L. Rostain, MD, MS
Associate Professor of Psychiatry and Pediatrics
Department of Psychiatry
Director, Adult ADHD Treatment and Research Program
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
PROGRAM PLANNING COMMITTEE
Chair
Eleanor Davidson, MD
Director, University Health Service
Case Western Reserve University
University Health Service
Cleveland, Ohio
Linda A. Bruce, MS, ANP-BC
Nurse Practitioner
Syracuse University
Syracuse, New York
Mary Hoban, PhD, CHES
Director, ACHA-NCHA Program Office
American College Health Association
Baltimore, Maryland
Kathleen MacLachlan, MS, ANP-BC
Nurse Practitioner
Syracuse University
Syracuse, New York
Michael Malmon-Berg, PhD
Psychologist
College of Wooster
Wooster, Ohio
Ralph Manchester, MD
Director, University Health Service
Associate Professor of Medicine
University of Rochester
Rochester, New York
Ric Underhile, PhD, LLPC, CHES
Prevention Practice Manager
Outside The Classroom, Inc.
Needham, Massachusetts
Susan Ainsworth, American College Health Association; Rosemary Hodgson, Mary Johnson, Rich Keenan, and Randy Robbin, Princeton Media Associates
DISCLOSURE INFORMATION
It is the policy of the American College Health Association (ACHA) to ensure balance, independence, objectivity, and scientific rigor in all its individually sponsored or joint-sponsored educational programs. All faculty participating in any ACHA sponsored program are expected to disclose to the participants any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the educational program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the program topic. The intent of this policy is not to prevent faculty with a potential conflict of interest from participating in an educational program. It is merely intended that any potential conflict should be identified openly so that participants may form their own judgments about the activity with a full disclosure of the facts. It remains for participants to determine whether the faculty's outside interests may reflect a possible bias in either the exposition or the conclusion presented.
The faculty has disclosed the following:
Dr. Greydanus: Speakers bureau — Cephalon
Dr. Rostain: Speakers bureau — Eli Lilly, Ortho-McNeil;
Consultant — Shire Pharmaceuticals
Ms. Ainsworth, Dr. Anderson, Ms. Bruce, Dr. Davidson, Dr. Hoban, Ms. Hodgson, Ms. Johnson, Mr. Keenan, Ms. MacLachlan, Dr. Malmon-Berg, Dr. Manchester, Dr. Ramsay, Mr. Robbin, and Dr. Underhile have indicated that they have no financial relationships to disclose.
OFF-LABEL PRODUCT DISCUSSION
Drs. Ramsay and Rostain will discuss off-label/unapproved use of the following agents for the treatment of ADHD: bupropion HCl, guanfacine, clonidine, imipramine, desipramine, and nortriptyline.
GRANT SUPPORT
The activity was supported by an unrestricted educational grant from Shire Pharmaceuticals.
